Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Dogwood Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 13 | 15 | +2 |
| Shares | 3.62M | 3.83M | +209.4K (+5.8%) |
| Value | $7.64M | $6.16M | −$1.47M (−19.3%) |
New holders (5)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 341,814 | $550.3K | 0.00% |
| Citadel Advisors LLC | 11,742 | $18.9K | 0.00% |
| Morgan Stanley | 2,222 | $3.58K | 0.00% |
| Jones Financial Companies LLLP | 160 | $264 | 0.00% |
| Barclays PLC | 157 | $253 | 0.00% |
Sold out (3)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Goldman Sachs Group Inc | 14,598 | $30.8K |
| Marshall Wace, LLP | 11,756 | $24.8K |
| BNP Paribas Arbitrage, SA | 2 | $4 |